bco pharma

Name

bco pharma

Legal name

BrePco Biopharma Limited

Website

https://bcopharma.com

Company type

Private

Operating status

Operating

Ownership category

akta.pro rank

Product category

Paediatric Critical Care Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Pediatric OTC Medicines (HLAIADAL)

Keywords

• Paediatric pharmaceuticals
• Dopamine formulation
• Neonatal critical care
• Hypotension infusion
• Sterile injectable drugs

Headquarters

HQ city

Dublin

HQ country

Ireland

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Licensing Royalties: BrePco Biopharma generates revenue through licensing agreements with Piramal Critical Care. PCC acquired commercialization rights for EU, UK, Norway, and South Africa markets, with BCO retaining marketing authorization holder status. The revenue model is based on licensing fees and ongoing royalties from product sales.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

BCO Pharma (BrePco Biopharma Limited) develops and holds the marketing authorisation for paediatric pharmaceutical formulations. Its commercial product is Neoatricon® (dopamine hydrochloride), a ready-to-use, pre-diluted sterile infusion solution available in two strengths (1.5 mg/mL in a 30 mL vial and 4.5 mg/mL in a 50 mL vial) indicated for the treatment of hypotension in haemodynamically unstable neonates, infants, and children under 18 years of age. The product is commercialised via a licensing partnership with Piramal Critical Care across the EU, UK, Norway and South Africa.

Product overview

BCO Pharma (BrePco Biopharma Limited) is a single-product pharmaceutical company focused on paediatric medicines. The company's sole product is Neoatricon® (dopamine hydrochloride), a ready-to-use infusion solution that is the only approved dopamine formulation for neonates, infants, and children in the EU and UK. Neoatricon® addresses the critical gap of off-label adult drug use in paediatric patients by providing pre-diluted, age-appropriate dosing in two strengths (1.5mg/mL and 4.5mg/mL). The product is commercialized in partnership with Piramal Critical Care for EU, UK, Norway, and South Africa markets.

Differentiator

Problem solved

Functional benefit

Products and services

• Neoatricon® (dopamine hydrochloride) Ready-to-use, age-appropriate sterile infusion solution of dopamine hydrochloride indicated for the treatment of hypotension in haemodynamically unstable neonates, infants and children under 18 years of age. Available in two strengths: 1.5 mg/mL (30 mL vial) for neonates, infants and children under 10 kg, and 4.5 mg/mL (50 mL vial) for patients 10 kg and above. Sold to hospitals for use in NICU/PICU settings via Piramal Critical Care in the EU, UK, Norway and South Africa.

Quantifiable outcome

• Error rates in administration of contemporaneously prepared sterile injectable solutions in hospitals are between 30-60%, with risk of non-sterility of up to 20% over the course of therapy
• +1 more outcomes

Segments2 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• Piramal Critical Care (PCC)coreChannel Partner/ Reseller/ Distributor · 1 October 2022Piramal Critical Care, a division of Piramal Pharma Limited and global leader in critical care medicines, acquired the EU, UK, Norway and South Africa commercialization rights for Neoatricon®. PCC is responsible for marketing, selling, and distributing Neoatricon® in these regions. PCC products are available in over 100 countries, with a focus on anaesthesia, pain management, intrathecal therapy, and critical care medicine. Neoatricon® represents PCC's expansion into a new therapeutic area.

Scale indicators3 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• Proveca Pharma: UK-based specialist pediatric pharma company that develops and licenses age-appropriate formulations of existing drugs for children. Highly comparable business model (specialty pediatric MAH + licensing to commercial partners) and a similar geographic focus on EU/UK regulatory pathways.
• Advicenne: France-based specialty pharmaceutical company focused on age-appropriate formulations for rare pediatric diseases, commercialized through EU hospital channels. Comparable small-cap, single-product-pivot pediatric pharma profile.
• Ethypharm: French specialty pharma focused on sterile injectable and pediatric formulations, with strong hospital distribution across Europe. Directly comparable formulation expertise and commercialization model to BCO's Neoatricon®.

Broad incumbents

• Chiesi Farmaceutici: Italy-headquartered specialty pharmaceutical company with a substantial pediatric and rare-disease portfolio, including hospital-channel critical care products across Europe. Larger and broader than BCO, but overlaps on EU-focused pediatric hospital pharma.
• Norgine: Netherlands-based specialty pharma with a hospital-focused portfolio across Europe. Larger and more diversified, but overlaps with BCO in EU hospital-channel distribution and specialty pharma positioning.
• Recordati: Italian specialty pharmaceutical group with established pediatric and rare-disease franchises (including through Orphan Europe). Overlaps with BCO on pediatric hospital pharma in the EU, though at significantly larger scale.
• Takeda (Shire): Global specialty/rare-disease pharma with a significant pediatric franchise inherited from Shire. Indirectly comparable through shared pediatric specialty positioning, though at vastly larger scale and broader geographic reach.

Emerging players

• Faes Farma: Spain-based specialty pharma with hospital and pediatric pharmaceutical products. Smaller and more emerging than the European incumbents, with comparable hospital-channel positioning in southern Europe.
• Clinigen Group: UK-headquartered specialty pharma providing access to unlicensed and pediatric medicines across Europe. Comparable niche positioning in pediatric pharma access and EU commercialization, though with a services-led model.

Others

• Sandoz: Global generics manufacturer with a pediatric formulations portfolio and hospital-channel presence. Not a direct pediatric-specialty competitor, but operates as a potential generic-entry threat into the broader pediatric injectable space.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/bco-pharma

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about bco pharma